Heparin Al

Heparin Al is a cutaneous formulation containing the active ingredient heparin sodium. It is supplied in the European Union market as a prescription‑only anticoagulant product. The preparation is designed for subcutaneous administration to provide antithrombotic activity by enhancing antithrombin III function, thereby reducing the risk of clot formation in patients at risk of thromboembolic events.

Heparin Al is indicated for the prevention and treatment of thromboembolic disorders and for prophylaxis of clot formation in patients who are at increased risk. It is commonly employed in clinical settings where rapid anticoagulation is required.

- Prevention of deep‑vein thrombosis (DVT) after surgery or immobilization - Treatment of acute pulmonary embolism - Management of unstable angina and myocardial infarction - Anticoagulation during hemodialysis or extracorporeal circulation - Prophylaxis of clotting in patients with atrial fibrillation or other high‑risk conditions

Heparin Al may cause a range of side effects, most of which are related to its anticoagulant activity. Patients should be monitored for both common and serious reactions.

Common: - Minor bruising or bleeding at the injection site - Mild thrombocytopenia (low platelet count) - Nausea or mild gastrointestinal discomfort - Transient elevation of liver enzymes - Localized skin irritation or erythema

Serious: - Major hemorrhage (internal or external) - Heparin‑induced thrombocytopenia (HIT) with paradoxical clotting - Severe allergic reactions, including anaphylaxis - Spontaneous bleeding into the central nervous system - Acute adrenal insufficiency in rare cases

Before initiating Heparin Al therapy, clinicians should assess patient history and monitor relevant parameters to minimize risks.

- Verify baseline platelet count and coagulation tests (aPTT, PT/INR) - Use caution in patients with a history of bleeding disorders or recent surgery - Adjust dose in renal or hepatic impairment as needed - Avoid use during pregnancy unless benefits outweigh risks; pregnancy category is unknown - Monitor for signs of heparin‑induced thrombocytopenia during treatment - Educate patients on proper injection technique to reduce local reactions - Discontinue if severe bleeding or allergic reaction occurs

Heparin Al can interact with several medications, affecting its anticoagulant effect or increasing bleeding risk.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) - High‑dose antiplatelet agents (e.g., aspirin, clopidogrel) without monitoring - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that impair platelet function - Thrombolytic agents (e.g., alteplase, streptokinase)

Use with caution: - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs - Corticosteroids, especially at high doses - Herbal supplements such as ginkgo biloba, garlic, or ginger - Vitamin K antagonists, requiring close INR monitoring - Certain antibiotics (e.g., quinolones) that may affect coagulation parameters